Gsk Share Discussion Threads

[tradermichael] 31/1/2024 09:17

Increased dividend of 16p declared for Q4 2023; 58p FY 2023; 60p expected for 2024

[tradermichael] 31/1/2024 08:36

GSK beats earnings expectations on blockbuster RSV jab
Ian Johnston in London

Strong vaccine sales powered British pharmaceutical company GSK to higher-than-expected earnings in 2023, as the company’s new RSV jab gained “blockbuster” status just over six months after its US launch.

Total sales rose 5 per cent year-on-year to £30.3bn, with adjusted operating profit of £8.8bn, ahead of analysts’ estimates. The company expects sales growth of 5 to 7 per cent in 2024, while it also raised its 2031 sales outlook to £38bn.

The business was helped by stronger than expected £1.2bn sales of Arexvy, its new vaccine for respiratory syncytial virus authorised in the US in May 2023, which has taken two-thirds of market share ahead of its only rival jab by Pfizer, while its shingles vaccine brought in £3.4bn.

[mj19] 31/1/2024 08:18

GSK, a pharmaceutical group, announced that 4Q adjusted EPS rose 25% on year to 28.9 pence and revenue was up 15% to 8.05 billion pounds, both at constant exchange rates. The company expects 2024 adjusted EPS growth of between 6% - 9%, compared with 16% in 2023.

[simon8] 31/1/2024 08:18

Really good results if i read them right, was expecting a lift in the share price .. well down we go, no surprise there - seems to happen so often with shares - good results and down they go.

[panache1] 31/1/2024 08:05

I'm in. 1525.60

[abdullla] 31/1/2024 08:04

Going down nothing new

[cumnor] 31/1/2024 07:46

A start, but dividend increase needed to be nearer 5% to drive the share price on from here, especially with Zantac litigation still ongoing. They need to deal with this.

[steeplejack] 31/1/2024 07:39

..."With this progress made, GSK has today announced upgraded outlooks, from those previously given, for the period 2021-2026 and for 2031. For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR basis and adjusted operating profit to increase more than 11%, on the same basis. This compares to previous outlooks of more than 5% and more than 10% respectively. Adjusted operating profit margin in 2026 is now expected to be more than 31%."Encouraging.

[igoe104] 31/1/2024 07:29

Happy with them Results, slight increase in the dividend as well.

[panache1] 31/1/2024 07:22

Any views on the results? Seem pretty good reading to me

[alibizzle] 30/1/2024 18:57

When will actually hear the zantac verdict ?

[rikky72] 30/1/2024 18:13

You would think it may go up but, as you say, who knows..Guess good pipeline progress + rising sales + resolution of Zantac will be the turbocharge we need..

[mj19] 30/1/2024 17:58

If this goes down tomorrow time to load up and hold

[tradermichael] 30/1/2024 10:34

GSK Q4 ex div is 22 Feb 2024

[abdullla] 29/1/2024 16:06

All the good news and GSK still going down

[tradermichael] 29/1/2024 07:58

GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline.

More than a fifth of adults over 60 in the US have received a vaccine for respiratory syncytial virus — an infection with cold-like symptoms — in the months since GSK and US rival Pfizer rolled out the first vaccines across the US.

GSK’s vaccine generated £709mn of sales in the third quarter of 2023. Analysts have predicted that it hit the $1bn milestone at which drugs become “blockbusters” in the final quarter of the year. GSK will disclose sales figures when it reports full-year results on Wednesday.

[abdullla] 26/1/2024 16:40

Results next week

[alibizzle] 26/1/2024 14:22

Encouraging but I would like to know if judge has ruled for plaintiff or GSK

[tradermichael] 26/1/2024 14:02

Shore Capital has lifted its target price from 1,850p to 2,000p and kept a 'buy' rating.

[tradermichael] 26/1/2024 13:58

A spokesman for GSK said: "We’re very confident in our position and continue to vigorously defend ourselves based on the facts and science of this litigation. Since 2019, there have been 15 peer-reviewed epidemiological studies on the effects of ranitidine use on humans which reflect the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk for any type of cancer.

“In Delaware, GSK is arguing that the court should follow the federal MDL court’s comprehensive Daubert ruling which, based on the scientific evidence, effectively dismissed all cases and claims related to the federal case’s five designated cancers. Like the federal courts, Delaware state courts apply the Daubert standard to determine the admissibility of expert evidence.

“The Delaware court are also considering the admissibility of evidence concerning five additional cancers, all of which should be rejected under the standards set by the MDL court, especially given that the MDL plaintiffs previously abandoned those claims due to a lack of scientific evidence."

[alibizzle] 26/1/2024 13:43

Will we actually get any news about court case outcome from Delaware soon

[tradermichael] 26/1/2024 13:18

1700p or 1800p .... still under-priced!

[dplewis1] 26/1/2024 08:09

Oops sorry.. 1700p

[dplewis1] 26/1/2024 08:08

Citigroup raises target price to 1800p from 1535p

[lovewinshatelosses] 26/1/2024 07:27

A return to the low 14's would tempt me to jump back in for a trade (or investment, if the trade goes wrong!) Not tempted at the current levels, personally. GLA.